Key points from latest quarterly.

64,000 global commercial beds contracted, a 127% increase compared to prior corresponding period
(PCP).

78% increase in cash receipts to $551,000 in Q3 FY23 vs PCP, with YTD cash receipts up 153% to
$1,504,000.

Cumulative Painchek pain assessments exceed 2,300,000 as of 31 March.

Circa 3500 pain assessments conducted daily.

PainChek is currently achieving 84% licence retention rates

PainChek is targeting US FDA clearance for market entry in 2024.

PainChek is now in communication with the Japanese regulatory authorities (PMDA) to determine
regulatory process and requirements.

Capital raise or finance needed in 3/6 months